01—Abstract
Summary
Summary of the 8-K filed September 2, 2025. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc. (DuPont) has entered into a Transaction Agreement dated August 29, 2025 with ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp. (together, Arclin) to sell its Aramids business, which includes Kevlar® and Nomex®.
The transaction values the business at approximately $1.8 billiona. At closing, DuPont is to receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a $300 million note receivable, and a non-controlling common equity interest in the future Arclin company valued at $325 million, expected to represent an approximate 17.5% stake at closing. Closing is subject to customary conditions, including the absence of certain injunctions and the expiration or termination of Hart-Scott-Rodino waiting periods and certain other approvals, including in the European Union, Japan, China, South Korea and the United Kingdom.
Either party may terminate if the transaction is not consummated by May 1, 2026, which may be extended twice by two months each if only regulatory approvals and closing-related conditions remain unsatisfied. The agreement also includes termination rights tied to material breaches or inaccurate representations.
The filing also attaches the Transaction Agreement as Exhibit 2.1, with schedules omitted under Item 601(a)(5) of Regulation S-K and certain provisions omitted under Item 601(b)(10)(iv). The forward-looking statements caution highlights risks around timing and completion, the value of the minority interest, and the impact of the transaction on DuPont's results of operations.
02—Key points
Key Highlights
- Agreement to sell the Aramids business (Kevlar® and Nomex®) to Arclin at a transaction value of approximately $1.8 billion
- Pre-tax cash proceeds at closing of approximately $1.2 billion, subject to customary transaction adjustments
- A $300 million note receivable and a non-controlling common equity interest in the future Arclin company valued at $325 million
- Expected approximate 17.5% stake in the future Arclin company at closing
- Closing subject to HSR Act and non-U.S. approvals, including the European Union, Japan, China, South Korea and the United Kingdom
- Outside date of May 1, 2026, extendable twice by two months each under specified conditions
- Transaction Agreement filed as Exhibit 2.1, with certain schedules and provisions omitted
03—Questions
Frequently Asked Questions
What is being sold, and for how much?
DuPont agreed to sell its Aramids business, which includes Kevlar® and Nomex®, to Arclin in a transaction valuing the business at approximately $1.8 billion.
What does DuPont receive at closing?
DuPont is to receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a $300 million note receivable, and a non-controlling common equity interest in the future Arclin company currently valued at $325 million.
What could prevent or delay the transaction from closing?
Closing requires the absence of certain injunctions and the expiration or termination of Hart-Scott-Rodino waiting periods and approvals or clearances under certain non-U.S. laws, including in the European Union, Japan, China, South Korea and the United Kingdom. The forward-looking statements also cite risks related to regulatory approvals, unforeseen liabilities, and the separation of business lines.
When can either party terminate the agreement?
Either the Company or Buyer may terminate if the transaction is not consummated on or before May 1, 2026, subject to two two-month extensions if all closing conditions other than regulatory approvals and closing-date conditions are satisfied. Either party may also terminate for material uncured inaccuracies in representations or breaches of covenants that cause a closing condition to fail.
What is the significance of DuPont's minority stake in the future Arclin company?
DuPont expects to hold an approximate 17.5% non-controlling stake in the future Arclin company at closing, currently valued at $325 million. The filing notes that the impact of owning this minority interest on DuPont's results of operations is a forward-looking risk factor.
04—Continue